Hepatic angiosarcoma may have fair survival nowadays

Neng-Chyan Huang1, Yau-Chang Kuo, Jui-Chin Chiang

  • 1From the Department of Emergency Medicine, Kaohsiung Veterans General Hospital, Kaohsiung (N-CH, Y-MH, Y-TC, S-RW, H-TC); National Yang-Ming University, School of Medicine, Taipei (N-CH, H-MW, Y-MH, Y-TC, S-RW, H-TC, J-SW); Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan (N-CH, J-CC, H-RG); Department of Occupational and Environmental Medicine, National Cheng Kung University and National Cheng Kung University Hospital, Tainan (Y-CK, H-RG); Department of Family Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung (J-CC); Department of Occupational Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung (J-CC); Division of Nephrology, Department of Internal Medicine, E-Da Hospital, Kaohsiung (S-YH); Department of Health Management, I-Shou University, Kaohsiung (S-YH); Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung (H-MW); Department of Health Care and Management, Yuh-Ing Junior College of Health Care and Management, Kaohsiung (Y-TC); Department of Pathology, Kaohsiung Veterans General Hospital, Kaohsiung (J-SW); Department of Radiation Oncology, Sin-Lau Christian Hospital, Tainan (S-YH); Department of Radiation Oncology, Chi Mei Liouying Hospital, Tainan (S-YH); and Department of Nursing, Chang Jung Christian University, Tainan, Taiwan (S-YH).

Medicine
|May 19, 2015
PubMed
Summary

Hepatic angiosarcoma (HAS) survival may be improving. Combination treatments like surgery and chemotherapy show promise for long-term outcomes in rare liver cancer patients.